{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positive+Choice&page=15", "query": { "intervention": "Positive Choice", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 499, "total_pages": 50, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positive+Choice&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positive+Choice&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T23:51:47.706Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01358877", "title": "A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4804, "start_date": "2011-11-08", "completion_date": "2024-11-28", "has_results": true, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-11-01T23:51:47.706Z", "location_count": 114, "location_summary": "Scottsdale, Arizona • Everett, California • Greenbrae, California + 92 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Everett", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Hayward", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01358877" }, { "nct_id": "NCT01204866", "title": "Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Allergic Reactions" ], "interventions": [ { "name": "Valortim and selected Components", "type": "BIOLOGICAL" }, { "name": "Valortim and Selected Components", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "PharmAthene, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "18 Years to 59 Years" }, "enrollment_count": 5, "start_date": "2010-07", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2010-09-24", "last_synced_at": "2026-11-01T23:51:47.706Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01204866" }, { "nct_id": "NCT02663518", "title": "A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Malignancies", "Solid Tumor" ], "interventions": [ { "name": "PF-0791800 (TTI-621)", "type": "DRUG" }, { "name": "PF-07901800 (TTI-621) plus Rituximab", "type": "DRUG" }, { "name": "PF-07901800 (TTI-621) plus Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 249, "start_date": "2016-01-28", "completion_date": "2022-11-23", "has_results": true, "last_update_posted_date": "2024-05-10", "last_synced_at": "2026-11-01T23:51:47.706Z", "location_count": 47, "location_summary": "Duarte, California • Palo Alto, California • Denver, Colorado + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02663518" }, { "nct_id": "NCT01154140", "title": "A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Squamous Lung Cancer" ], "interventions": [ { "name": "treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 343, "start_date": "2011-01-13", "completion_date": "2016-11-30", "has_results": true, "last_update_posted_date": "2017-11-06", "last_synced_at": "2026-11-01T23:51:47.706Z", "location_count": 84, "location_summary": "Beverly Hills, California • Fontana, California • Loma Linda, California + 53 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fontana", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01154140" }, { "nct_id": "NCT01579617", "title": "e-SiHLE: An Internet Pregnancy Prevention for Older Teenage Girls", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pregnancy", "Sexually Transmitted Infections" ], "interventions": [ { "name": "BUtiful.", "type": "BEHAVIORAL" }, { "name": "DIVAS.", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Tulane University Health Sciences Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "19 Years", "sex": "FEMALE", "summary": "18 Years to 19 Years · Female only" }, "enrollment_count": 637, "start_date": "2012-08", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2016-12-19", "last_synced_at": "2026-11-01T23:51:47.706Z", "location_count": 6, "location_summary": "New Orleans, Louisiana", "locations": [ { "city": "New Orleans", "state": "Louisiana" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01579617" }, { "nct_id": "NCT06218303", "title": "Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ductal Carcinoma in Situ" ], "interventions": [ { "name": "MUC1 Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Hiltonol®", "type": "DRUG" }, { "name": "Aromatase Inhibitor", "type": "DRUG" }, { "name": "Selective estrogen receptor modulator (SERM)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Finn, Olivera, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 50, "start_date": "2024-02-07", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-11-01T23:51:47.706Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06218303" }, { "nct_id": "NCT03811652", "title": "A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer Squamous (NSCLC-Sq)", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Small Cell Lung Cancer (SCLC)", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Colorectal Cancer (CRC)", "Metastatic Castration-resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "MEDI7247", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "18 Years to 101 Years" }, "enrollment_count": 8, "start_date": "2018-12-20", "completion_date": "2019-12-10", "has_results": false, "last_update_posted_date": "2019-12-30", "last_synced_at": "2026-11-01T23:51:47.706Z", "location_count": 2, "location_summary": "Huntersville, North Carolina • Nashville, Tennessee", "locations": [ { "city": "Huntersville", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03811652" }, { "nct_id": "NCT04501016", "title": "A Stepped Care Approach to Treating Tobacco Use in Rural Veterans", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Tobacco Cessation" ], "interventions": [ { "name": "Tailored behavioral counseling", "type": "BEHAVIORAL" }, { "name": "Tobacco cessation pharmacotherapy", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "Iowa City Veterans Affairs Medical Center", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 100, "start_date": "2020-09", "completion_date": "2023-09", "has_results": false, "last_update_posted_date": "2020-08-06", "last_synced_at": "2026-11-01T23:51:47.706Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04501016" }, { "nct_id": "NCT02745743", "title": "Phase I Trial of BAY1251152 for Advanced Blood Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "BAY1251152", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2016-06-17", "completion_date": "2018-08-03", "has_results": false, "last_update_posted_date": "2019-09-19", "last_synced_at": "2026-11-01T23:51:47.706Z", "location_count": 3, "location_summary": "New York, New York • The Bronx, New York • Nashville, Tennessee", "locations": [ { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02745743" }, { "nct_id": "NCT05215171", "title": "World Trade Center Particulate Matter Induced Cardiorespiratory and Vascular Dysfunction: a MultiOmic Approach (CaRVD)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cardiorespiratory and Vascular Dysfunction", "Obstructive Airway Disease" ], "interventions": [], "intervention_types": [], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "21 Years to 90 Years" }, "enrollment_count": 100, "start_date": "2023-03-30", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-11-01T23:51:47.706Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05215171" } ] }